https://scholars.lib.ntu.edu.tw/handle/123456789/487348
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | Hsu W.-L. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.creator | Yang C.-H.;Cheng A.-L.;Hsu W.-L.;CHIH-HUNG HSU;Hsu C.;Lin C.-C. | - |
dc.date.accessioned | 2020-04-28T07:25:32Z | - |
dc.date.available | 2020-04-28T07:25:32Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750445933&doi=10.1007%2fs10637-006-9004-9&partnerID=40&md5=f3f73d458dbc2b2064efd43d4c526c06 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/487348 | - |
dc.description.abstract | Background: Arsenic trioxide induces growth inhibition and apoptosis in human hepatocellular carcinoma (HCC) cell lines. A phase II trial was conducted to evaluate the efficacy and toxicity of single-agent arsenic trioxide in patients with HCC. Methods: Inclusion criteria included advanced HCC patients to whom no standard palliative treatment can be offered, good organ function and liver function reserve. Patients received arsenic trioxide 0.16-0.24 mg/kg per day for 5-6 days per week for 3-4 weeks, followed by one-week rest. Tumor response was assessed every 2 cycles. Primary endpoint was the percentage of patients with 6-month disease stabilization. Results: Twenty-nine patients (median age, 59) with locally advanced or metastatic HCC received a total of 61 cycles (median, 2; range, 1-6). One patient had partial response. Three patients had disease stabilization for at least six months. The 6-month tumor stabilization rate was 14% (95% CI, 1-27). The median overall survival was 4.8 months (95% CI, 1.4-8.2) and one-year survival was 30%. Conclusion: Single-agent arsenic trioxide using this dose schedule is not active against advanced HCC. ? 2006 Springer Science+Business Media, LLC. | - |
dc.relation.ispartof | Investigational New Drugs | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | arsenic trioxide; asadin; aspartate aminotransferase; bilirubin; chlorotrianisene; creatinine; doxorubicin; gemcitabine; thalidomide; adult; aged; allergic reaction; alopecia; aminotransferase blood level; anemia; anorexia; article; bilirubin blood level; cancer survival; clinical article; clinical trial; constipation; controlled clinical trial; controlled study; creatinine blood level; diarrhea; drug dose regimen; drug efficacy; fatigue; female; fever; human; hypomagnesemia; hyponatremia; infection; leukopenia; liver cell carcinoma; liver toxicity; male; nephrotoxicity; neutropenia; phase 2 clinical trial; pigment disorder; priority journal; pruritus; QT prolongation; side effect; sinus tachycardia; thrombocytopenia; unspecified side effect; vomiting; weight reduction; Adult; Aged; Antineoplastic Agents; Arsenicals; Carcinoma, Hepatocellular; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxides; Survival Analysis; Treatment Outcome | - |
dc.title | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s10637-006-9004-9 | - |
dc.identifier.pmid | 16937079 | - |
dc.identifier.scopus | 2-s2.0-33750445933 | - |
dc.relation.pages | 77-84 | - |
dc.relation.journalvolume | 25 | - |
dc.relation.journalissue | 1 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。